Across TCGA pan-cancer cohorts, CDX2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of CDX2’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where CDX2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CDX2 is over-expressed in tumor.
COAD are the cancer types where CDX2 tumor–normal differential expression is most reproducible.